The GPHF-Minilab™ – Protection Against Counterfeit Medicines

Due to increasing counterfeit medicines proliferation and its associated health risks, drug quality control in the distribution systems of developing countries has become more and more important for consumer protection today. Africa, parts of Asia, and parts of Latin America have areas where more than 30% of the medicines on sale can be counterfeit.

The GPHF-Minilab takes the basic drug testing scheme published by the World Health Organization (WHO) some thirty years ago into the 21st century. Overall, more than 730 Minilabs have been supplied across 94 countries out of which Cambodia, Laos, Vietnam, Madagascar, Nigeria and Tanzania adopted the technology for post-marketing antimalarial drug quality monitoring already.

(Visited 30 times, 1 visits today)
This entry was posted in Essential Medicines, General. Bookmark the permalink.